Rupatadine : global safety evaluation in allergic rhinitis and urticaria
- Author
- Vanesa González-Núñez, Claus Bachert (UGent) and Joaquim Mullol
- Organization
- Abstract
- Introduction: Rupatadine is a second-generation H-1-antihistamine with dual affinity for histamine H-1 and PAF receptors. Rupatadine is indicated for the treatment of allergic rhinitis and urticaria. Areas covered: A Medline search was conducted to identify preclinical and clinical studies of rupatadine. This was supplemented with additional articles obtained from online sources. The focus of this review is on the safety profile of rupatadine. Expert opinion: The review of these data indicates that rupatadine is highly selective for histamine H-1-receptors, exhibits additional PAF antagonism in in vitro and in vivo studies, does not cross the blood-brain barrier, and has similar adverse events comparable with other second-generation antihistamines. Rupatadine is a safe and well tolerated drug in patients over 2years old, with no central nervous system or cardiovascular effects and it can be taken with or without foods.
- Keywords
- Rupatadine, H-1-receptor antagonist, H-1-antihistamine, PAF antagonist, allergic rhinitis, seasonal, perennial, intermittent, persistent, urticaria, chronic spontaneous urticaria, therapeutic use, pharmacodynamics, pharmacokinetics, safety, second-generation antihistamine, PLATELET-ACTIVATING-FACTOR, CHRONIC IDIOPATHIC URTICARIA, ASTHMA ARIA GUIDELINES, TNF-ALPHA RELEASE, CETIRIZINE 10 MG, CELL LINE HMC-1, DOUBLE-BLIND, HEALTHY-VOLUNTEERS, 2ND-GENERATION ANTIHISTAMINES, MAST-CELLS
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 1.42 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8511449
- MLA
- González-Núñez, Vanesa, et al. “Rupatadine : Global Safety Evaluation in Allergic Rhinitis and Urticaria.” EXPERT OPINION ON DRUG SAFETY, vol. 15, no. 10, 2016, pp. 1439–48, doi:10.1080/14740338.2016.1221399.
- APA
- González-Núñez, V., Bachert, C., & Mullol, J. (2016). Rupatadine : global safety evaluation in allergic rhinitis and urticaria. EXPERT OPINION ON DRUG SAFETY, 15(10), 1439–1448. https://doi.org/10.1080/14740338.2016.1221399
- Chicago author-date
- González-Núñez, Vanesa, Claus Bachert, and Joaquim Mullol. 2016. “Rupatadine : Global Safety Evaluation in Allergic Rhinitis and Urticaria.” EXPERT OPINION ON DRUG SAFETY 15 (10): 1439–48. https://doi.org/10.1080/14740338.2016.1221399.
- Chicago author-date (all authors)
- González-Núñez, Vanesa, Claus Bachert, and Joaquim Mullol. 2016. “Rupatadine : Global Safety Evaluation in Allergic Rhinitis and Urticaria.” EXPERT OPINION ON DRUG SAFETY 15 (10): 1439–1448. doi:10.1080/14740338.2016.1221399.
- Vancouver
- 1.González-Núñez V, Bachert C, Mullol J. Rupatadine : global safety evaluation in allergic rhinitis and urticaria. EXPERT OPINION ON DRUG SAFETY. 2016;15(10):1439–48.
- IEEE
- [1]V. González-Núñez, C. Bachert, and J. Mullol, “Rupatadine : global safety evaluation in allergic rhinitis and urticaria,” EXPERT OPINION ON DRUG SAFETY, vol. 15, no. 10, pp. 1439–1448, 2016.
@article{8511449, abstract = {{Introduction: Rupatadine is a second-generation H-1-antihistamine with dual affinity for histamine H-1 and PAF receptors. Rupatadine is indicated for the treatment of allergic rhinitis and urticaria. Areas covered: A Medline search was conducted to identify preclinical and clinical studies of rupatadine. This was supplemented with additional articles obtained from online sources. The focus of this review is on the safety profile of rupatadine. Expert opinion: The review of these data indicates that rupatadine is highly selective for histamine H-1-receptors, exhibits additional PAF antagonism in in vitro and in vivo studies, does not cross the blood-brain barrier, and has similar adverse events comparable with other second-generation antihistamines. Rupatadine is a safe and well tolerated drug in patients over 2years old, with no central nervous system or cardiovascular effects and it can be taken with or without foods.}}, author = {{González-Núñez, Vanesa and Bachert, Claus and Mullol, Joaquim}}, issn = {{1474-0338}}, journal = {{EXPERT OPINION ON DRUG SAFETY}}, keywords = {{Rupatadine,H-1-receptor antagonist,H-1-antihistamine,PAF antagonist,allergic rhinitis,seasonal,perennial,intermittent,persistent,urticaria,chronic spontaneous urticaria,therapeutic use,pharmacodynamics,pharmacokinetics,safety,second-generation antihistamine,PLATELET-ACTIVATING-FACTOR,CHRONIC IDIOPATHIC URTICARIA,ASTHMA ARIA GUIDELINES,TNF-ALPHA RELEASE,CETIRIZINE 10 MG,CELL LINE HMC-1,DOUBLE-BLIND,HEALTHY-VOLUNTEERS,2ND-GENERATION ANTIHISTAMINES,MAST-CELLS}}, language = {{eng}}, number = {{10}}, pages = {{1439--1448}}, title = {{Rupatadine : global safety evaluation in allergic rhinitis and urticaria}}, url = {{http://doi.org/10.1080/14740338.2016.1221399}}, volume = {{15}}, year = {{2016}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: